Possibilities of predicting the risk of cardiorenal syndrome in patients with chronic kidney disease on the background of congenital malformations of the urinary system

BACKGROUND. Currently, there is no doubt that there is a close relationship between the condition of the kidneys and the cardiovascular system. Neurohormonal systems various parts long-term hyperactivation is important in the development of pathological processes. Natriuretic peptides provide cardio and renoprotective effects, inhibit the activity of the renin-angiotensin-aldosterone system (RAAS). AIM. To establish the prognostic significance of determining the concentration of natriuretic peptides in comparison with the activity of RAAS in children with congenital malformations of the urinary system to assess the risk of cardiovascular complications.

PATIENTS AND METHODS. 76 patients with congenital malformations OUS aged 3 to 18 years were examined: – 40 children with congenital vesicoureteral reflux, – 18 children with hydronephrosis, 18 children with other forms of OUS dysembryogenesis ( 10 patients with renal agenesis, 8-with hypoplasia). The control group consisted of 10 clinically healthy children of the appropriate age. The following parameters were determined in the blood by the enzyme immunoassay: renin, aldosterone, n-terminal propeptide of natriuretic hormone (NТ-рroВNР).

RESULTS. Hyperproduction of NТ-рroВNР was observed in 61.8 % of patients, stimulation of renin and/or aldosterone production in 39.5 % of cases. Elevated levels of natriuretic peptides were found in 32.8 % of cases in 25 children with congenital OUS defects without signs of arterial hypertension (AH) and left ventricular hypertrophy (LVH). Significantly higher concentrations of (NТ-рroВNР), renin, and aldosterone are recorded in patients with AH and LVH.

CONCLUSION. The increased level of natriuretic peptides is noted earlier than the clinical and instrumental signs of heart dysfunction are noticeable, it is important in identifying early stages of cardiovascular complications, evaluating the prognosis, and in justifying renoprotective treatment in pediatric Nephrology practice.

1. Ignatova MS. Children's Nephrology. Medicine, Moscow, 2016. 526 p. (In Russ.)

2. Pytel AYa. Selected chapters of Nephrology and urology. Part 2. Pytel AYa, Goligorsky SD. Medicine, Moscow, 2018. 352 p. (In Russ.)

3. Smirnov AV, Dobronravov VA, Kayukov IG. The cardiorenal continuum: Pathogenetic bases of preventive nephrology. Nephrology (Saint-Petersburg) 2005;9(3):7-15. (In Russ.) doi: 10.24884/1561-6274-2005-9-3-7-15

4. Beresneva ON, Parastaeva M, Kulikov AN et al. Features of myocardial remodeling rats while reducing the mass of existing nephrons. Nephrology (Saint-Petersburg) 2019;23(supplement 1):18. (In Russ.) doi: 10.36485/1561-6274-2019-23-5-18-43

5. Ivanova GT, Lobov GI, Beresneva ON, Parastaevа MM. Changes in the reactivity of large vessels of rats with functioning nephrons experimental decrease in mass. Nephrology (Saint-Petersburg) 2019;23(supplement 1): 29. (In Russ.) doi: 10.36485/1561-6274-2019-23-5-18-43

6. Murkamilov IT, Satkynalieva ZT, Sabirov IS, Fomin VV. Cardiorenal relations with syndrome of obstructive sleep apnea. Nephrology (Saint-Petersburg) 2019;23(supplement 1):35. (In Russ.) doi: 10.36485/1561-6274-2019-23-5-18-43

7. Shilov EM. Nephrology. Clinical recommendations. EM. Shilov, AV Smirnov, NL Kozlovskaya. GEOTAR-Media, 2020. 856 p. (In Russ.)

8. Mukhin NA. Introduction to Nephrology. Argument, Moscow, 2016; 279 p. (In Russ.)

9. Sokolova IB, Ivanova GT, Lobov GI. NO-dependent mechanism of pial arteries affected tonus regulation by nephrectomy. Nephrology (Saint-Petersburg) 2019;23 (supplement 1):39. (In Russ.) doi: 10.36485/1561-6274-2019-23-5-18-43

10. Titov VN. Inversion of ideas about the biological role of the renin-angiotensin-aldosterone system and the function of blood pressure as a regulator of metabolism. Clinical and laboratory diagnostics 2015;2:4-13

11. Sheiman DA. Рathophysiology of the kidney. Binom, M., 2015; 206 p. (In Russ.)

12. Fedotova IN, Belopol'skij AA, Sturov NV. The diagnostic value of NT-proBNP in cardiac patients. Difficult patient 2013;(7):22-32 (In Russ.)

13. Нагорная НВ, Пшеничная ЕВ, Бордюгова ЕВ. Клиническое значение натрийуретического пептида у пациентов с хронической сердечной недостаточностью. Здоровье ребенка 2011;2(29):115-120 Nagornaya NV, Pshenichnaya EV, Bordyugova YeV. Clinical value of natriuretic peptide in patients with chronic heart failure patients. Child's health 2011;2(29):115-120 (In Russ.)

14. Markers of cardiovascular disease. Available from: http://www.biochemmack.ru/upload/uf/411/411436f66d7a694a862947cab2868f8b.pdf (In Russ.)

15. Federal guidelines for the provision of medical care for children with chronic heart failure. Available from: http://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoypomoshchi/_kr_ hsn.pdf (In Russ.)

16. Gracheva VV, Karpova IV, Yakimovsky AF. (edit. AF Yakimovsky). Basic physiology of the kidney. Spetslit, Saint Petersburg, 2017; 55 p. (In Russ.)